Federal subpoenas are latest in opioid actions.
Major pharmaceutical manufacturers and distributors are likely facing a criminal investigation by the US government over the opioid epidemic, according to news reports. Many pharma makers are already facing a multitude of lawsuits for their alleged role in fueling opioid addiction.
At least 6 drug companies have received subpoenas from federal prosecutors, indicating that a broad criminal investigation is probably underway, The Washington Postreported.
Related: FDA warns opioid repackers
The country’s 2 largest wholesale drug distributors, McKesson and AmerisourceBergen, have received subpoenas from federal prosecutors, along with Mallinckrodt Pharmaceuticals, Teva Pharmaceutical, Johnson & Johnson, and Amneal Pharmaceuticals, The Washington Post said.
Teva reported that it received a subpoena from the Justice Department for “documents relating to the manufacture, marketing and sale of opioids,” along with a grand jury subpoena from Brooklyn prosecutors. The government is looking for information on how Teva distributes opioid medications and prevents narcotics from being diverted for illegal use, The Washington Post said.
Related: Startling number of patients inappropriately prescribed fentanyl
McKesson reported that it received grand jury subpoenas in April and June “seeking documents related to the company’s anti-diversion policies and procedures and its distribution” of prescription opioids.
The opioid crisis has escalated in recent years. For example, overdoses soared 30% from July 2016 through September 2017. And a study published earlier this year said that many patients who were prescribed fentanyl should not have received the drug.
Read more: Amid opioid epidemic, FDA clears powerful painkiller
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
August 1st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More